Prophylaxis with rivaroxaban after laparoscopic sleeve gastrectomy could reduce the frequency of portoniesenteric venous thrombosis

Simple item page
dc.contributor.authorRodriguez, J., I
dc.contributor.authorKobus, V
dc.contributor.authorTellez, I
dc.contributor.authorPerez, G.
dc.date.accessioned2025-01-23T19:47:05Z
dc.date.available2025-01-23T19:47:05Z
dc.date.issued2020
dc.description.abstractINTRODUCTION Portal and mesenteric venous thrombosis is a rare but potentially serious complication after laparoscopic sleeve gastrectomy. There are no consistent studies that prove the safety and effectiveness of oral anticoagulant thromboprophylaxis with rivaroxaban after laparoscopic sleeve gastrectomy. The objective was to evaluate the effect of rivaroxaban on the frequency of portal and mesenteric venous thrombosis and its safety profile after laparoscopic sleeve gastrectomy.
dc.description.abstractMATERIALS AND METHODS This retrospective analysis of prospectively collected data includes all laparoscopic sleeve gastrectomies performed by a single surgeon at Pontificia Universidad Catolica de Chile Hospital between January 2009 and June 2019. All patients received low molecular weight heparin thromboprophylaxis during the whole hospital stay. Between July 2012 and June 2019, patients received additional post-discharge thromboprophylaxis with rivaroxaban. Patient demographics, impaired renal, post-surgical portal and mesenteric venous thrombosis, and bleeding episodes were registered.
dc.description.abstractRESULTS A total of 516 patients were identified; 95 patients were excluded. Results for 421 patients were analysed: 198 received only intrahospital thromboprophylaxis (group 1) and 223 received additional post-discharge thromboprophylaxis with rivaroxaban (group 2). There was no statistically significant difference between the two groups concerning age, sex and body mass index. In group 1, four cases of portal and mesenteric venous thrombosis were registered and no cases were reported in group 2 (p < 0.05). All cases occurred before 30 days after surgery. No bleeding episodes and no adverse reactions were detected in group 2.
dc.description.abstractCONCLUSIONS Thromboprophylaxis during the whole hospital stay (two to three days), followed by rivaroxaban 10mg once daily for 10 days after discharge (completing in total 13-14 days of prophylaxis), could reduce cases of post-surgical portal and mesenteric venous thrombosis without an increase in bleeding complications.
dc.fuente.origenWOS
dc.identifier.doi10.1308/rcsann.2020.0209
dc.identifier.eissn1478-7083
dc.identifier.issn0035-8843
dc.identifier.urihttps://doi.org/10.1308/rcsann.2020.0209
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/100346
dc.identifier.wosidWOS:000584413800024
dc.issue.numero9
dc.language.isoen
dc.pagina.final716
dc.pagina.inicio712
dc.revistaAnnals of the royal college of surgeons of england
dc.rightsacceso restringido
dc.subjectBariatric surgery
dc.subjectLaparoscopic sleeve gastrectomy
dc.subjectVenous thrombosis
dc.subjectPortal vein
dc.subjectPortal and mesenteric venous thrombosis
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleProphylaxis with rivaroxaban after laparoscopic sleeve gastrectomy could reduce the frequency of portoniesenteric venous thrombosis
dc.typeartículo
dc.volumen102
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas